Form 4: Immunovant CLO Sells Shares to Cover Tax Withholding

Immunovant, Inc. Chief Legal Officer Christopher Van Tuyl sold shares to cover tax obligations related to RSU vesting, a non-discretionary transaction.

Summary

• Christopher Van Tuyl, Chief Legal Officer of Immunovant, Inc., reported the sale of 1,143 shares of common stock on July 8, 2026, at a weighted average price of $39.53 per share.
• An additional 63 shares were sold on the same date at a weighted average price of $39.99 per share.
• These sales were conducted to cover tax withholding obligations arising from the vesting of 3,174 restricted stock units (RSUs) that were granted on April 1, 2025.
• The company's election to require satisfaction of tax withholding through a 'sell to cover' transaction mandated these sales, meaning they were not discretionary.
• Following these transactions, Van Tuyl beneficially owns 179,454 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. The transaction is a standard, non-discretionary event related to RSU vesting and tax obligations, not indicative of the executive's confidence in the company's future performance.

Positives

• The transactions were non-discretionary, indicating they were a necessary consequence of RSU vesting and tax obligations rather than a reflection of the executive's view on the stock's future performance.
• The executive continues to hold a significant number of shares (179,454) after the tax-related sale.

Negatives

• A portion of the executive's vested equity was sold, reducing their direct holdings.

Risks

• The filing does not explicitly mention any new risks or challenges.
• The 'sell to cover' transaction, while standard for tax withholding, can sometimes be misinterpreted by the market as a sale driven by negative sentiment.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on a past transaction.

Management Comments

• The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary transaction by the Reporting Person.

Industry Context

StockSavvy.ai notes that 'sell to cover' transactions are a common and expected practice for executives when RSUs vest, particularly in the biotechnology and pharmaceutical sectors where equity-based compensation is prevalent and tax liabilities can be substantial. This type of transaction is generally not viewed as a negative signal regarding the company's prospects.

Stakeholder Impact

• Shareholders: The sale is a routine tax-related event and is not expected to have a significant impact on the share price or company operations. The executive retains a substantial beneficial ownership.

Next Steps

• No specific future actions or milestones are mentioned in this filing.

Key Dates

Keywords

Immunovant, IMVT, Form 4, Insider Transaction, Stock Sale, RSU Vesting, Tax Withholding, Christopher Van Tuyl, Chief Legal Officer